Literature DB >> 16647138

Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders.

John W Phillis1, Lloyd A Horrocks, Akhlaq A Farooqui.   

Abstract

Three enzyme systems, cyclooxygenases that generate prostaglandins, lipoxygenases that form hydroxy derivatives and leukotrienes, and epoxygenases that give rise to epoxyeicosatrienoic products, metabolize arachidonic acid after its release from neural membrane phospholipids by the action of phospholipase A(2). Lysophospholipids, the other products of phospholipase A(2) reactions, are either reacylated or metabolized to platelet-activating factor. Under normal conditions, these metabolites play important roles in synaptic function, cerebral blood flow regulation, apoptosis, angiogenesis, and gene expression. Increased activities of cyclooxygenases, lipoxygenases, and epoxygenases under pathological situations such as ischemia, epilepsy, Alzheimer's disease, Parkinson disease, amyotrophic lateral sclerosis, and Creutzfeldt-Jakob disease produce neuroinflammation involving vasodilation and vasoconstriction, platelet aggregation, leukocyte chemotaxis and release of cytokines, and oxidative stress. These are closely associated with the neural cell injury which occurs in these neurological conditions. The metabolic products of docosahexaenoic acid, through these enzymes, generate a new class of lipid mediators, namely docosatrienes and resolvins. These metabolites antagonize the effect of metabolites derived from arachidonic acid. Recent studies provide insight into how these arachidonic acid metabolites interact with each other and other bioactive mediators such as platelet-activating factor, endocannabinoids, and docosatrienes under normal and pathological conditions. Here, we review present knowledge of the functions of cyclooxygenases, lipoxygenases, and epoxygenases in brain and their association with neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16647138     DOI: 10.1016/j.brainresrev.2006.02.002

Source DB:  PubMed          Journal:  Brain Res Rev        ISSN: 0165-0173


  131 in total

1.  Targeted knock-down of a structurally atypical zebrafish 12S-lipoxygenase leads to severe impairment of embryonic development.

Authors:  Ulrike Haas; Elisabeth Raschperger; Mats Hamberg; Bengt Samuelsson; Karl Tryggvason; Jesper Z Haeggström
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

Review 2.  NSAIDs in the treatment and/or prevention of neurological disorders.

Authors:  Parto S Khansari; Leanne Coyne
Journal:  Inflammopharmacology       Date:  2012-01-10       Impact factor: 4.473

3.  Long-chain and very long-chain polyunsaturated fatty acids in ocular aging and age-related macular degeneration.

Authors:  Aihua Liu; James Chang; Yanhua Lin; Zhengqing Shen; Paul S Bernstein
Journal:  J Lipid Res       Date:  2010-08-05       Impact factor: 5.922

4.  The fatty acid oxidation product 15-A3t-isoprostane is a potent inhibitor of NFκB transcription and macrophage transformation.

Authors:  Joshua D Brooks; Erik S Musiek; Tyler R Koestner; Jeannette N Stankowski; Jocelyn R Howard; Enrico M Brunoldi; Alessio Porta; Giuseppe Zanoni; Giovanni Vidari; Jason D Morrow; Ginger L Milne; BethAnn McLaughlin
Journal:  J Neurochem       Date:  2011-09-23       Impact factor: 5.372

5.  ALOX12 in human toxoplasmosis.

Authors:  William H Witola; Susan Ruosu Liu; Alexandre Montpetit; Ruth Welti; Magali Hypolite; Mary Roth; Ying Zhou; Ernest Mui; Marie-France Cesbron-Delauw; Gilbert J Fournie; Pierre Cavailles; Cordelia Bisanz; Kenneth Boyer; Shawn Withers; A Gwendolyn Noble; Charles N Swisher; Peter T Heydemann; Peter Rabiah; Stephen P Muench; Rima McLeod
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

6.  Flavocoxid attenuates gentamicin-induced nephrotoxicity in rats.

Authors:  Dalia H El-Kashef; Asmaa E El-Kenawi; Ghada M Suddek; Hatem A Salem
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-08-15       Impact factor: 3.000

7.  Very long-chain fatty acid accumulation causes lipotoxic response via 5-lipoxygenase in cerebral adrenoleukodystrophy.

Authors:  Mushfiquddin Khan; Jaspreet Singh; Anne G Gilg; Takuhiro Uto; Inderjit Singh
Journal:  J Lipid Res       Date:  2010-02-20       Impact factor: 5.922

Review 8.  CNS immune privilege: hiding in plain sight.

Authors:  Monica J Carson; Jonathan M Doose; Benoit Melchior; Christoph D Schmid; Corinne C Ploix
Journal:  Immunol Rev       Date:  2006-10       Impact factor: 12.988

9.  Vitamin K prevents oxidative cell death by inhibiting activation of 12-lipoxygenase in developing oligodendrocytes.

Authors:  Jianrong Li; Hong Wang; Paul A Rosenberg
Journal:  J Neurosci Res       Date:  2009-07       Impact factor: 4.164

10.  Class A scavenger receptor-mediated macrophage adhesion requires coupling of calcium-independent phospholipase A(2) and 12/15-lipoxygenase to Rac and Cdc42 activation.

Authors:  Dejan M Nikolic; Ming C Gong; John Turk; Steven R Post
Journal:  J Biol Chem       Date:  2007-09-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.